Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00162474
Status:
UNKNOWN
Last Update Posted:
2018-06-12
First Post:
2005-09-11
Brief Title:
Determinants of Warfarin Metabolism
Sponsor:
Hadassah Medical Organization
Organization:
Hadassah Medical Organization
Study Overview
Official Title:
Correlation Between Phenotypic Activity of CYP2C9 and Genetic Polymorphism in CYP2C9 and Warfarin Metabolism
Status:
UNKNOWN
Status Verified Date:
2018-03
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The anticoagulant effect of warfarin varies greatly among individuals Some of this variability is attributed to differences in the activity of CYP2C9 the predominant enzyme involved in the metabolism of S-warfarin
The present study is designed to define the differences in warfarin metabolism among healthy individuals carrying different CYP2C9 genotypes In addition the study will define the correlation between the phenytoin metabolic ratio a marker of CYP2C9 activity in vivo and warfarin metabolism
The present study is designed to define the differences in warfarin metabolism among healthy individuals carrying different CYP2C9 genotypes In addition the study will define the correlation between the phenytoin metabolic ratio a marker of CYP2C9 activity in vivo and warfarin metabolism
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None